Research and industry
At the Early Drug Development Center (EDDC), we focus on treating solid tumors with experimental targeted therapy, immunotherapy, cell therapies, and therapeutic drug monitoring of anticancer drugs. Our phase 1 and 2 studies are based on fundamental knowledge about cancer and cell mechanisms, with the aim to obtain new treatment options. Our focus areas are immunotherapy, image-guided therapy, personalized medicine, and survivorship. You can find more information about the research groups of NKI that we collaborate with here.
With our high-quality standards, protocols, and clear agreements, we ensure constructive collaboration with CROs and pharmaceutical companies. By working together with our partners, we aim to reach the highest standard and quality in research activities.
We work with different departments that are essential for early drug development. Our facilities and resources include (amongst others) radiology, hospital pharmacy, nuclear medicine, pathology, general clinical laboratories, data management, contract management and a CRU. We are always looking for new partners and collaborations. If you are interested in partnering with the EDDC, you can send an email to phase1@nki.com. In this section of the website, you can find more information about our focus areas, the facilities and resources at the EDDC, and our partners.
Collaboration with CROs and pharmaceutical companies
With our high-quality standards, protocols, and clear agreements, we ensure constructive collaboration with CROs and pharmaceutical companies. By working together with our partners, we aim to reach the highest standard and quality in research activities.
We work with different departments that are essential for early drug development. Our facilities and resources include (amongst others) radiology, hospital pharmacy, nuclear medicine, pathology, general clinical laboratories, data management, contract management and a CRU. We are always looking for new partners and collaborations. If you are interested in partnering with the EDDC, you can send an email to phase1@nki.com. In this section of the website, you can find more information about our focus areas, the facilities and resources at the EDDC, and our partners.
Focus Areas
The Netherlands Cancer Institute has a comprehensive end-to-end experience, ranging from basic research to pre-clinical and clinical studies. At the Early Drug Development Center (EDDC), we focus on Industry-sponsored early clinical research, Investigator Initiated Studies (IIS) and translational work.
Facilities and resources
We work with different departments that are essential for early drug development. Our facilities and resources include radiology, hospital pharmacy, nuclear medicine, pathology and general clinical laboratories.
Our partners
At the Early Drug Development Center (EDDC), we work closely and effectively with others. We understand that through collaborations, we are able to obtain expertise and patient data needed to tackle the global cancer challenge and work towards a 21st-century learning health system.